A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study by Salvador Fudio, Laura Pérez-Ramos, Eduardo Asín-Prieto, Ali Zeaiter, Rubin Lubomirov

Get full text

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. by Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M Francesch, Pablo M Avilés, Salvador Fudio

Get full text

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS by Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M. Francesch, Pablo M. Avilés, Salvador Fudio

Get full text

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug... by Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov

Get full text

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma by María Victoria Mateos, Felipe Prosper, Jesús Martin Sánchez, Enrique M. Ocio, Albert Oriol, Cristina Motlló, Jean‐Marie Michot, Isidro Jarque, Rebeca Iglesias, María Solé, Sara Martínez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag

Get full text